Q1 EPS Estimates for Blueprint Medicines Reduced by Wedbush

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Research analysts at Wedbush dropped their Q1 2025 earnings estimates for shares of Blueprint Medicines in a research report issued on Wednesday, April 16th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings of ($0.58) per share for the quarter, down from their previous estimate of ($0.57). Wedbush currently has a "Outperform" rating and a $128.00 target price on the stock. The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share. Wedbush also issued estimates for Blueprint Medicines' Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at $0.00 EPS, FY2026 earnings at $0.44 EPS, FY2027 earnings at $4.01 EPS and FY2028 earnings at $8.60 EPS.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Several other research analysts have also commented on the stock. Scotiabank began coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Needham & Company LLC reiterated a "buy" rating and set a $133.00 price target on shares of Blueprint Medicines in a research report on Tuesday, April 8th. Morgan Stanley initiated coverage on Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective for the company. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $124.95.

Blueprint Medicines Stock Performance

Blueprint Medicines stock traded up $1.94 during mid-day trading on Friday, reaching $85.35. The company's stock had a trading volume of 303,559 shares, compared to its average volume of 768,040. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $121.90. The business has a 50 day moving average price of $87.99 and a 200-day moving average price of $93.17. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of -79.03 and a beta of 0.75.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd grew its holdings in shares of Blueprint Medicines by 27.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 2,662 shares of the biotechnology company's stock valued at $246,000 after buying an additional 576 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Blueprint Medicines during the 3rd quarter valued at about $202,000. Synovus Financial Corp increased its holdings in shares of Blueprint Medicines by 4.0% in the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company's stock valued at $2,224,000 after purchasing an additional 922 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock worth $3,259,000 after purchasing an additional 265 shares during the period. Finally, Exome Asset Management LLC acquired a new stake in shares of Blueprint Medicines during the third quarter worth approximately $3,395,000.

Insiders Place Their Bets

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now directly owns 69,266 shares in the company, valued at $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.